By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Morphotek said today that it has entered into two agreements with Fox Chase Cancer Center to acquire clinical samples that it will use to develop companion diagnostic assays for use with drugs currently under development at Morphotek.

Morphotek, a subsidiary of Eisai, said it will fund prospective and archival sample collection programs at Fox Chase to obtain samples from patients who are newly diagnosed with cancer or are being treated for a variety of tumor types.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.